Arecor Therapeutics and Skye Bioscience have agreed a formulation development collaboration to develop a novel, higher concentration formulation of Skye’s CB1 inhibitor, nimacimab. Skye is evaluating nimacimab, a first-in-class CB1-inhibiting monoclonal antibody, in its Phase IIa CBeyond clinical trial in patients with obesity and overweight. Data from the initial 26-week treatment period is anticipated in […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!